StroMel is under clinical development by Akan Biosciences and currently in Phase II for Osteoarthritis. According to GlobalData, Phase II drugs for Osteoarthritis have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how StroMel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
StroMel overview
StroMel is under development for the treatment of knee osteoarthritis. The drug candidate comprises of autologous mesenchymal stem cells (MSC). It is administered through intraarticular route.
Akan Biosciences overview
Akan Biosciences is a biotechnology and cellular therapy company developing next-generation injectable products for the treatment of degenerative diseases and injury. It is headquartered in Germantown, Maryland, the US.
For a complete picture of StroMel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
